Victorian med tech innovation achieving overseas success
Atmo Biosciences produces a world-first medical device, providing hope to millions of people with common gut disorders
Victorian medical technology company Atmo Biosciences is taking its world-first gas-sensing capsule to the US market.
Gut issues are a common problem. More than 40% of people worldwide are likely to experience one.
These debilitating conditions cause:
- nausea
- vomiting
- diarrhoea
- abdominal pain.
They’re often difficult to diagnose or treat, leaving many undiagnosed or with ongoing symptoms.
Atmo’s capsule is changing that.
When swallowed, this exciting technology measures data in the gut in real time. It helps doctors diagnose digestive disorders quickly and effectively.
Atmo is a spin out from RMIT University, where the innovative ingestible capsule was first developed.
Investment from Breakthrough Victoria has helped the company commercialise its innovative product and launch it on the US market.
This local innovation is driving global impact and creating jobs in Victoria.
Atmo Biosciences’s success highlights the strength of Victoria’s rapidly growing health technologies sector. Worth $21.4 billion, the sector generates $3.8 billion in exports and employs over 51,700 people across the state.